Promising biomarkers are being developed to predict disease outcome and response to therapy in children with juvenile idiopathic arthritis, childhood lupus nephritis and juvenile idiopathic inflammatory myopathies. These advances are expected to facilitate risk stratification, diagnosis and management of these patients, and thereby lead to more rational and effective clinical care.
- Alessandro Consolaro
- Giulia C. Varnier
- Angelo Ravelli
